Consensus on the utility of bone markers in the malignant bone disease setting

Robert Coleman, Luis Costa, Fred Saad, Richard Cook, Peyman Hadji, Evangelos Terpos, Patrick Garnero, Janet Brown, Jean Jacques Body, Matthew Smith, Ker Ai Lee, Pierre Major, Meletios Dimopoulos, Allan Lipton

Research output: Contribution to journalReview article

55 Citations (Scopus)

Abstract

Biochemical markers of bone turnover provide insight into ongoing rates of skeletal metabolism and tumor-bone interactions in patients with malignant bone disease. This article reviews the available recent evidence assessing the potential of bone markers for detecting and monitoring malignant bone lesions in patients with advanced cancers, and for assessing overall skeletal health and response to antiresorptive therapies in patients at all stages of cancer progression. Most data thus far are for urinary N-terminal cross-linked telopeptide of type I collagen (NTX) in predicting risks of skeletal morbidity and death and monitoring response to zoledronic acid in patients with bone metastases. Ongoing studies are evaluating such correlations for other markers and therapies. Emerging evidence suggests that bone markers may help identify patients at high risk for bone metastasis or bone lesion progression, thereby allowing improved follow-up. Results from ongoing clinical trials evaluating such potential applications of bone markers are awaited.

Original languageEnglish (US)
Pages (from-to)411-432
Number of pages22
JournalCritical Reviews in Oncology/Hematology
Volume80
Issue number3
DOIs
StatePublished - Dec 1 2011

Fingerprint

Bone Diseases
Bone and Bones
zoledronic acid
Neoplasm Metastasis
Neoplasms
Bone Remodeling
Collagen Type I
Biomarkers
Clinical Trials
Morbidity
Health
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Coleman, Robert ; Costa, Luis ; Saad, Fred ; Cook, Richard ; Hadji, Peyman ; Terpos, Evangelos ; Garnero, Patrick ; Brown, Janet ; Body, Jean Jacques ; Smith, Matthew ; Lee, Ker Ai ; Major, Pierre ; Dimopoulos, Meletios ; Lipton, Allan. / Consensus on the utility of bone markers in the malignant bone disease setting. In: Critical Reviews in Oncology/Hematology. 2011 ; Vol. 80, No. 3. pp. 411-432.
@article{307d925118e9463ba2dd34eb019d4d9c,
title = "Consensus on the utility of bone markers in the malignant bone disease setting",
abstract = "Biochemical markers of bone turnover provide insight into ongoing rates of skeletal metabolism and tumor-bone interactions in patients with malignant bone disease. This article reviews the available recent evidence assessing the potential of bone markers for detecting and monitoring malignant bone lesions in patients with advanced cancers, and for assessing overall skeletal health and response to antiresorptive therapies in patients at all stages of cancer progression. Most data thus far are for urinary N-terminal cross-linked telopeptide of type I collagen (NTX) in predicting risks of skeletal morbidity and death and monitoring response to zoledronic acid in patients with bone metastases. Ongoing studies are evaluating such correlations for other markers and therapies. Emerging evidence suggests that bone markers may help identify patients at high risk for bone metastasis or bone lesion progression, thereby allowing improved follow-up. Results from ongoing clinical trials evaluating such potential applications of bone markers are awaited.",
author = "Robert Coleman and Luis Costa and Fred Saad and Richard Cook and Peyman Hadji and Evangelos Terpos and Patrick Garnero and Janet Brown and Body, {Jean Jacques} and Matthew Smith and Lee, {Ker Ai} and Pierre Major and Meletios Dimopoulos and Allan Lipton",
year = "2011",
month = "12",
day = "1",
doi = "10.1016/j.critrevonc.2011.02.005",
language = "English (US)",
volume = "80",
pages = "411--432",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

Coleman, R, Costa, L, Saad, F, Cook, R, Hadji, P, Terpos, E, Garnero, P, Brown, J, Body, JJ, Smith, M, Lee, KA, Major, P, Dimopoulos, M & Lipton, A 2011, 'Consensus on the utility of bone markers in the malignant bone disease setting', Critical Reviews in Oncology/Hematology, vol. 80, no. 3, pp. 411-432. https://doi.org/10.1016/j.critrevonc.2011.02.005

Consensus on the utility of bone markers in the malignant bone disease setting. / Coleman, Robert; Costa, Luis; Saad, Fred; Cook, Richard; Hadji, Peyman; Terpos, Evangelos; Garnero, Patrick; Brown, Janet; Body, Jean Jacques; Smith, Matthew; Lee, Ker Ai; Major, Pierre; Dimopoulos, Meletios; Lipton, Allan.

In: Critical Reviews in Oncology/Hematology, Vol. 80, No. 3, 01.12.2011, p. 411-432.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Consensus on the utility of bone markers in the malignant bone disease setting

AU - Coleman, Robert

AU - Costa, Luis

AU - Saad, Fred

AU - Cook, Richard

AU - Hadji, Peyman

AU - Terpos, Evangelos

AU - Garnero, Patrick

AU - Brown, Janet

AU - Body, Jean Jacques

AU - Smith, Matthew

AU - Lee, Ker Ai

AU - Major, Pierre

AU - Dimopoulos, Meletios

AU - Lipton, Allan

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Biochemical markers of bone turnover provide insight into ongoing rates of skeletal metabolism and tumor-bone interactions in patients with malignant bone disease. This article reviews the available recent evidence assessing the potential of bone markers for detecting and monitoring malignant bone lesions in patients with advanced cancers, and for assessing overall skeletal health and response to antiresorptive therapies in patients at all stages of cancer progression. Most data thus far are for urinary N-terminal cross-linked telopeptide of type I collagen (NTX) in predicting risks of skeletal morbidity and death and monitoring response to zoledronic acid in patients with bone metastases. Ongoing studies are evaluating such correlations for other markers and therapies. Emerging evidence suggests that bone markers may help identify patients at high risk for bone metastasis or bone lesion progression, thereby allowing improved follow-up. Results from ongoing clinical trials evaluating such potential applications of bone markers are awaited.

AB - Biochemical markers of bone turnover provide insight into ongoing rates of skeletal metabolism and tumor-bone interactions in patients with malignant bone disease. This article reviews the available recent evidence assessing the potential of bone markers for detecting and monitoring malignant bone lesions in patients with advanced cancers, and for assessing overall skeletal health and response to antiresorptive therapies in patients at all stages of cancer progression. Most data thus far are for urinary N-terminal cross-linked telopeptide of type I collagen (NTX) in predicting risks of skeletal morbidity and death and monitoring response to zoledronic acid in patients with bone metastases. Ongoing studies are evaluating such correlations for other markers and therapies. Emerging evidence suggests that bone markers may help identify patients at high risk for bone metastasis or bone lesion progression, thereby allowing improved follow-up. Results from ongoing clinical trials evaluating such potential applications of bone markers are awaited.

UR - http://www.scopus.com/inward/record.url?scp=79958775704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958775704&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2011.02.005

DO - 10.1016/j.critrevonc.2011.02.005

M3 - Review article

VL - 80

SP - 411

EP - 432

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -